Activation of mTOR Ameliorates Fragile X Premutation rCGG Repeat-Mediated Neurodegeneration

作者：Lin, Yunting; Tang, Chengyuan; He, Hua; Duan, Ranhui^*

来源：PLos One, 2013, 8(4): e62572.

DOI：10.1371/journal.pone.0062572

• EPITHELIAL-MESENCHYMAL TRANSITION
• CEREBELLAR-TREMOR/ATAXIA-SYNDROME
• MAMMALIAN TARGET
• MOUSE MODEL
• RAPAMYCIN MTOR
• OLIGODENDROCYTE DIFFERENTIATION
• POLYGLUTAMINE EXPANSIONS
• INTRANUCLEAR INCLUSIONS
• DOPAMINERGIC-NEURONS
• HUNTINGTONS-DISEASE

Fragile X associated tremor/ataxia syndrome (FXTAS) is a late onset neurodegenerative disorder caused by aberrant expansion of CGG repeats in 5' UTR of FMR1 gene. The elevated mRNA confers a toxic gain-of-function thought to be the critical event of pathogenesis. Expressing rCGG(90) repeats of the human FMR1 5'UTR in Drosophila is sufficient to induce neurodegeneration. Rapamycin has been demonstrated to attenuate neurotoxicity by inducing autophagy in various animal models of neurodegenerative diseases. Surprisingly, we observed rapamycin exacerbated rCGG(90)-induced neurodegenerative phenotypes through an autophagy-independent mechanism. CGG(90) expression levels of FXTAS flies exposed to rapamycin presented no significant differences. We further demonstrated that activation of the mammalian target of rapamycin (mTOR) signaling could suppress neurodegeneration of FXTAS. These findings indicate that rapamycin will exacerbate neurodegeneration, and that enhancing autophagy is insufficient to alleviate neurotoxicity in FXTAS. Moreover, these results suggest mTOR and its downstream molecules as new therapeutic targets for FXTAS by showing significant protection against neurodegeneration.

• 出版日期2013-4-23
• 单位中南大学